Acute Drug-Induced Cholestatic Syndrome in Basedow Graves’ Disease

1. Cooper D, Landenson P. The thyroid gland. In: Gardner D, Shoback D, ed. Greenspan’s Basic & Clinical Endocrinology. 10th ed. McGraw-Hill Education, 2017; p. 171-239.Search in Google Scholar

2. Kahaly G, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce S. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7:167-186.10.1159/000490384Search in Google Scholar

3. Cipolla C, Graceffa G, Calamia S, et al. The value of total thyroidectomy as the definitive treatment for Graves’ disease: A single centre experience of 594 cases. J Clin Transl Endocrinol. 2019;16:100-183.10.1016/j.jcte.2019.100183Search in Google Scholar

4. Akmal A, Kung J. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. Expert Opin Drug Saf. 2014;13:1397-1406.10.1517/14740338.2014.953796Search in Google Scholar

5. Karras S, Memi E, Kintiraki E, Krassas G. Pathogenesis of propylthiouracil-related hepatotoxicity in children: present concepts. J Pediatr Endocrinol Metab. 2012;25:623-630.10.1515/jpem-2012-0059Search in Google Scholar

6. Nakamura H, Noh J, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Caused by Graves’ Disease. J Clin Endocrinol Metab. 2007;92:2157-2162.10.1210/jc.2006-2135Search in Google Scholar

7. Wang M, Lee W, Huang T, Chu C, Hsieh C. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78:619-629.10.1111/bcp.12336Search in Google Scholar

8. Rivkees S, Szarfman A. Dissimilar Hepatotoxicity Profiles of Propylthiouracil and Methimazole in Children. J Clin Endocrinol Metab. 2010;95:3260-3267.10.1210/jc.2009-2546Search in Google Scholar

9. Oshima T, Maeda H, Takayashu T, et al. An autopsy case of sudden death due to hyperthyroidism. Nihon Hoigaku Zasshi. 1990;44:365-370.Search in Google Scholar

10. Heidari R, Niknahad H, Jamshidzadeh A, Eghbal M, Abdoli N. An Overview on the Proposed Mechanisms of Antithyroid Drugs-Induced Liver Injury. Adv Pharm Bull. 2015;5:1-11.Search in Google Scholar

11. Chen W, Zhu Z, Wang C, Chien M. Cholestasis and Acute Cholecystitis in Hyperthyroidism Treated With Methimazole. Int J Gerontol. 2009;3:248-250.10.1016/S1873-9598(10)70009-0Search in Google Scholar

12. Tseng F, Chen Y, Chi Y, Chen P, Yang W. Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves’ disease patients with hyperthyroidism or subjects with euthyroidism. Medicine (Baltimore). 2019;98:e14862.10.1097/MD.0000000000014862642655430882687Search in Google Scholar

13. Mikhail N. Methimazole-induced Cholestatic Jaundice. South Med J. 2004;97:178-182.10.1097/01.SMJ.0000054690.98272.B114982270Search in Google Scholar

14. Li X, Jin S, Fan Y, et al. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves’ disease patients. Biomed Pharmacother. 2019;117:109095.10.1016/j.biopha.2019.10909531202168Search in Google Scholar

15. Cooper D. Antithyroid Drugs. N Engl J Med. 2005;352:905-917.10.1056/NEJMra04297215745981Search in Google Scholar

16. Chang L, Chang C, Chen P, et al. Thyrotropin receptor antibodies and a genetic hint in antithyroid drug-induced adverse drug reactions. Expert Opin Drug Saf. 2018;17:775-784.10.1080/14740338.2018.150274730067105Search in Google Scholar

17. Heidari R, Ahmadi F, Rahimi H, et al. Exacerbated liver injury of antithyroid drugs in endotoxin-treated mice. Drug Chem Toxicol. 2018;42:615-623.10.1080/01480545.2018.145966829722569Search in Google Scholar

18. Sundaresh V, Brito J, Thapa P, Bahn R, Stan M. Comparative Effectiveness of Treatment Choices for Graves’ Hyperthyroidism: A Historical Cohort Study. Thyroid. 2017;27:497-505.10.1089/thy.2016.0343538542928049375Search in Google Scholar